By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Helicos BioSciences said in a filing with the US Securities and Exchange Commission Friday that it has approximately $200,000 in cash and cash equivalents remaining and will require "significant additional capital" to continue operations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.